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s u m m a r y
The influence of Mycobacterium tuberculosis (MTB) lineages/sublineages on unfavorable tuberculosis (TB)
treatment outcomes is poorly understood. We investigated the effects of Beijing genotype sublineages
and other factors contributing to treatment outcome. Patients newly diagnosed with sputum smear-
positive and culture-positive TB in Hanoi, Vietnam, participated in the study. After receiving anti-TB
treatment, they were intensively followed up for the next 16 months. MTB isolates collected before
treatment were subjected to drug susceptibility testing, and further analyzed to determine MTB (sub)
lineages and their clonal similarities. Of 430 patients, 17 had treatment failure and 30 had TB recurrence.
Rifampicin resistance was associated with treatment failure {adjusted odds ratio ¼ 6.64 [95% confidence
interval (CI), 1.48e29.73]}. The modern Beijing genotype was significantly associated with recurrent TB
within 16 months [adjusted hazard ratio ¼ 3.29 (95% CI, 1.17e9.27)], particularly after adjustment for the
relevant antibiotic resistance. Human immunodeficiency virus coinfection and severity on chest radio-
graphs were not significantly associated with unfavorable outcomes. Our findings provide further un-
derstanding of the influence of MTB strains on unfavorable treatment outcomes. Multiple risk factors
should be considered for the optimal management of TB.
© 2015 Elsevier Ltd. All rights reserved.
1. Introduction
Tuberculosis (TB) is a chronic infection that continues to be a
major public health problemworldwide, with 8.6million new cases
and 1.3 million deaths in 2012 [1]. Unfavorable treatment outcome,
including treatment failure and recurrence, is a major risk factor for
drug resistance in TB [2], which increases the TB burden [3].
Recurrence is defined as an active TB episode that reoccurs after
initial successful treatment. According to the World Health
Organization (WHO) Report 2013 [1], of the 6.1 million cases of TB
that were identified, 0.3 million had recurrent episodes (including
exogenous reinfection and endogenous reactivation) after being
previously cured.
Previous studies have evaluated risk factors for TB recurrence,
which include severity of disease indicated on chest radiographs
(e.g., the presence of cavitation and the extent of pulmonary
involvement) [4,5], drug resistance [6], microbial load at diagnosis,
or human immunodeficiency virus (HIV) coinfection [4]. Because
recurrence occurs as a result of dynamic interactions between host
and pathogen [7], the Mycobacterium tuberculosis (MTB) genotype
should also be considered a potential risk factor for recurrence. The
MTB Beijing genotype strains account for the majority of the East
Asian lineage, one of the sevenmajor MTB lineages in the world [8],
and are becoming widespread even outside Asia [9]. These strains
appear to be associated with an increased risk of TB recurrence,
according to several reports [10e13].
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The Beijing genotype strains belong to one of the two major
sublineages, ancient (atypical) and modern (typical) types, based
on the absence or presence of an IS6110 insertion in a particular
chromosomal position designated as the NTF region of the MTB
genome [14]. Molecular epidemiological studies have characterized
possible differences in phenotypes between the sublineages:
strains of the modern Beijing sublineage are adapted to spread and
cause disease more easily than those of the ancient sublineage in
different regions of the world [15,16], whereas the ancient Beijing
sublineage is often associated with drug resistance, including
multidrug resistance (MDR) or extremely drug-resistant TB [17],
pyrazinamide (PZA or Z) or rifampicin (RMP or R) resistance [18],
and isoniazid (INH or H) or streptomycin (SM or S) resistance [19].
However, associations between Beijing sublineages and unfavor-
able treatment outcomes have not yet been fully investigated.
Vietnam is a Southeast Asian country stretching over 1,800 km
from north to south. It is one of 22 countries with a high TB prev-
alence worldwide (218 per 100,000 in 2012) [1]. Although the
treatment success rate for new cases was reported to be between
85% and 93% from 1995 to 2011 [1], more than 7200 cases were
identified as recurrent TB in 2012 [1]. Regional differences in MTB
genotypes have been observed. In southern Vietnam, the modern
sublineage is reportedly predominant over the ancient sublineage
[20]; and the Beijing genotype, as a whole, has been reported as a
risk factor for TB recurrence, when compared with non-Beijing
genotypes [13]. In Hanoi, in northern Vietnam, the ancient sub-
lineage (37.5%) is more prevalent than the modern sublineage
(20.9%) [19]. In the present study, we investigated whether these
two Beijing sublineages are similarly associated with treatment
failure or recurrence in newly diagnosed active pulmonary TB pa-
tients in Hanoi.
2. Materials and methods
2.1. Ethics statement
Written informed consent was obtained from each participant;
parents provided written informed consent for minors. This study
was approved by the ethical committees of theMinistry of Health of
Vietnam, the National Center for Global Health and Medicine, and
the Research Institute of Tuberculosis, Japan Anti-Tuberculosis As-
sociation, Japan.
2.2. Study sites, recruitment of patients, and sample collection
Patients were recruited within part of a cohort study reported
elsewhere [21]. Residential areas of the patients were divided into
three categories based mainly on population density, year of estab-
lishment, andurbanization speed: suburban (1500e2500 individuals/
km2), old urban (25,000e26,000 individuals/km2), and new urban
(2800e5300 individuals/km2) areas [22]. In summary, patients over
16 years old residing in the Hanoi area who suffered from newly
diagnosed smear-positive pulmonary TB and agreed to participate in
the studywere recruited from July2007 toMarch2009.Thesepatients
were interviewed by pretrained healthcare staff using a structured
questionnaire. Before initiation of treatment, sputum specimens and
blood samples were collected. Patients then received the standard 8-
month regimen that was commonly administered during the study
period in Vietnam: INH, RMP, PZA, and SM or ethambutol (EMB or E)
for 2months followed by INH and EMB for 6months [2S(E)HRZ/6HE].
Drug susceptibility testingwas performed retrospectively on theMTB
isolates, which were stored in a freezer before anti-TB treatment
began. Thus, susceptibility test results were not available while
deciding treatment schedules, and the standard regimen was
followed according to the national TB control program guidelines at
the time of the study.
During treatment, culture tests were repeated when smear tests
were confirmed positive at 2, 5, or 7 months. During the 16-month
post-treatment follow-up, sputum smear and culture tests were
scheduled at 2, 4, 7, 10, and 16 months for all enrolled cases.
2.3. Identification of MTB, drug susceptibility testing and molecular
genotyping
MTB, drug susceptibility, and molecular genotypes were iden-
tified as previously reported [19,22]. In short, the niacin test was
initially used for MTB identification, and drug susceptibility testing
was performed for INH, SM, RMP, and EMB on the basis of the
proportional method recommended by WHO. Beijing and non-
Beijing strains were distinguished by a single-nucleotide poly-
morphism (SNP) at position 779,615 [23] and spoligotyping results
[24]. Their genotypes were identified using the international MTB
database (SpolDB4) [25]. Ancient and modern Beijing genotypes
were further distinguished using the polymerase chain reaction
method [26]. Variable number of tandem repeat (VNTR) analysis
was performed using the international standard 24 mycobacterial
interspersed repetitive unit-VNTR system [27] with four additional
loci recommended for the Beijing genotype strains [28]. Genetic
clustering was defined by a complete match of the VNTR profile of
the 28 loci.
2.4. Definitions of treatment failure and TB recurrence
Treatment failure and TB recurrence were defined on the basis
of the WHO Global Tuberculosis Report 2013 [1]. In summary,
treatment failure was noted when the smear and culture were
positive at 5 months or when the smear was positive but culture
was not performed, clinical and/or chest radiography findings
indicated failure, and the category switched to the regimen for
retreatment. Recurrence was noted when patients were cured after
treatment and then suffered a second TB episode. The second
episode was confirmed if the sputum culture was positive at the
time of recurrence, or if a culture result was not available or was
difficult to assess (<5 colonies) [29], but the smear was positive in
patients with clinical and/or chest radiographic abnormalities
indicating the necessity of retreatment. After the expert committee
members' review in Vietnam, the category II regimen (2SHRZE/
1HRZE/5H3R3E3) for retreatment was started in all patients with
treatment failure or TB recurrence.
2.5. Statistical analysis
Logistic regression models were used to investigate factors
possibly associated with treatment failure, and adjusted odds ratios
(aORs) and 95% confidence intervals (CIs) were calculated. Using a
logistic regression model, treatment failure was set as a binominal
outcome variable, and the explanatory variables were MTB line-
ages/sublineages and relevant antibiotic resistance. The log-rank
test for equality across strata was also used to investigate the as-
sociation between MTB lineages and time to recurrence. After
testing the proportional hazard assumption, Cox models were used
to assess multiple risk factors for recurrence, similar to the logistic
regression models. Adjusted hazard ratios (aHRs) and 95% CIs were
calculated. Statistical analysis was performed using Stata version 12
(StataCorp, College Station, TX, USA), and P values of <0.05 were
considered statistically significant.
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3. Results
3.1. Characteristics of the study population
In the present study, 489 patients were diagnosed with bacte-
riologically confirmed pulmonary TB, of whom 430 completed the
directly observed treatment, short-course (DOTS) program at the
study sites (Figure 1). Adherence to anti-TB therapy was supervised
by the healthcare staff, in cooperation with the patients' family
members, under the DOTS strategy of the national TB control
program.
Of the 430 patients, 183 (42.6%) were aged <35 years, and 341
(79.3%) were male. HIV coinfection was seen in 22 patients (5.1%),
290 patients (70.2%) had cavities on chest radiographs at diagnosis,
and 70 patients (16.9%) had infiltrates spreading to more than half
of the lung zones. Among the 413 patients in whom MTB strains
were genotyped, Beijing genotype strains were identified in 240
(58.1%) patients, of which 152 belonged to the ancient Beijing
sublineages, accounting for 36.8% of all strains tested, and 88
strains belonged to the modern Beijing sublineages, accounting for
21.3% of all the strains tested (Table 1).
Treatment outcomes are illustrated in Figure 1. Treatment
failure was noted in 17 (4.0%, 95% CI, 2.3e6.3) of the 430 patients.
The remaining 413 patients were considered cured, and 403 of
them entered the follow-up period. The median of follow-up time
was 484 days (95% CI, 483e487 days) after completion of treat-
ment. Recurrence was observed in 30 patients (7.4%, 95% CI,
5.1e10.5) during this period. Of these, 21 patients (70.0%)
exhibited culture-positive results. Culture results were not avail-
able or were difficult to assess for the remaining 9 patients
(30.0%), but all had smear-positive results with clinical/radio-
graphic changes. All 30 patients with recurrent TB received a
retreatment regimen of 2SHRZE/1HRZE/5H3R3E3. The median
time to recurrence was 137 days (95% CI, 110e218 days) after the
end of their previous treatment episode.
3.2. Sublineages of Beijing genotype strains and treatment failure
MTB genotypes were divided into three categories: modern
Beijing, ancient Beijing, and non-Beijing, including East Afri-
caneIndian type. Univariate analysis indicated that infection with
modern Beijing MTB strains was significantly associated with
treatment failure [OR ¼ 4.15 (95% CI, 1.01e17.00)], whereas infec-
tion with ancient Beijing strains was not, when non-Beijing types
were set as a reference category. Treatment failure was significantly
associated with resistance to SM, RMP, INH, or MDR; positivity of
smear testing after the first 2 months of treatment; and the pres-
ence of infiltrates in more than half of the lung on chest radio-
graphs. Age, sex, presence of cavities on radiographs, HIV status,
and clustering status of the MTB strains were not significantly
associated with treatment failure (Table 2).
Multivariate analysis indicated that RMP resistance was signif-
icantly associated with treatment failure [aOR ¼ 6.64 (95% CI,
1.48e29.73)]; however, SM resistance, INH resistance, and infection
with the modern Beijing sublineage were not (Table 2). When we
replaced RMP and INH resistance by MDR in the same model, MDR
Figure 1. Study flow. TB: tuberculosis; MTB: Mycobacterium tuberculosis; NTM: non-
tuberculous mycobacterium; DOTS: directly observed treatment, short-course.
Table 1
Characteristics of patients with smear-positive culture-positive pulmonary tuber-
culosis who finished an 8-month treatment course.
Total number
tested
Number
of patients
%
Age (in years) 430
<25 61 14.2
25e34.9 122 28.4
35e44.9 78 18.1
45e54.9 100 23.3
55 69 16.1
Sex 430
Male 341 79.3
Female 89 20.7
Body mass index 430
<16 56 13.0
16e18.4 176 40.9
18.5 198 46.1
Residential area 430
Suburban 95 22.1
New urban 199 46.3
Old urban 136 31.6
Smoking habit 429
Smoker 164 38.2
Ex-smoker 120 28.0
Nonsmoker 145 33.8
HIV status 428
Positive 22 5.1
Negative 406 94.9
Infiltrate on chest radiograph 414
3 zones 344 83.1
>3 zones 70 16.9
Cavity on chest radiograph* 413
Yes 290 70.2
No 123 29.8
Drug resistant profile 430
Sensitive to all four drugs testedy 272 63.3
Any resistance to isoniazid 113 26.3
Any resistance to streptomycin 111 25.8
Any resistance to rifampicin 15 3.5
Any resistance to ethambutol 9 2.1
Multidrug resistance 13 3.0
MTB lineage/sublineage 413
Modern Beijing 88 21.3
Ancient Beijing 152 36.8
Non-Beijing 173 41.9
HIV: Human immunodeficiency virus; MTB: Mycobacterium tuberculosis.
* The number of patients from whom available information was obtained was
listed. The information on cavitary lesion was available in 413 patients, although
414 chest x-ray films were taken.
y Includes isoniazid, streptomycin, rifampicin, and ethambutol.
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was also significantly associated with treatment failure
[aOR ¼ 10.23 (95% CI, 2.27e46.15)] (table not shown). Smear test
results at month 2 and chest X-ray (CXR) findings may represent
disease severity [30] as a result of hostepathogen interaction or
phenotypic consequences of variations in MTB lineages/sub-
lineages [31]. Therefore, we did not include them in the final model
for the purposes of the present study.
3.3. Sublineages of Beijing genotype strains and TB recurrence
First, patients infected with a Beijing strain had a significantly
shorter time to TB recurrence, confirmed by the log-rank test
(P ¼ 0.0211) (Figure 2A). Second, patients with the modern Beijing
strains had a significantly shorter time to TB recurrence than pa-
tients with non-Beijing strains (P ¼ 0.0213) (Figure 2B). However,
no other pairwise comparisons of sublineages were statistically
significant (data not shown). The numbers of patients showing
recurrence during the observation period were 9 (11.3%) among the
80 patients with the modern Beijing MTB strain, 13 (9.1%) among
the 143 patients with the ancient Beijing strain, and 6 (3.6%) among
the 165 patients with other (non-Beijing) strains. The proportions
of patients with TB recurrence within one year (12 months) after
completing treatment for the prior TB episode were 11.2% (95% CI,
6.0e20.3) in those infected with the modern Beijing MTB strain,
8.5% (4.9e14.4) in those with the ancient Beijing strain, and 3.7%
(1.7e8.0) with other strains.
Assuming that coexisting drug resistance might influence the
effect of Beijing MTB lineages/sublineages on recurrence, we next
investigated the effects of recurrence-associated factors using Cox
proportional hazard models for univariate and multivariate ana-
lyses. Using the non-Beijing strains as the reference group, infection
with the modern Beijing strains was significantly associated with
time to TB recurrence in the univariate analysis [HR ¼ 3.16 (95% CI,
1.13e8.89)] and the multivariate analysis with adjustment for drug
resistance [aHR ¼ 3.29 (95% CI, 1.17e9.27)]. Infection with the
ancient Beijing strains was not significantly associated with time to
TB recurrence (Table 3).
Resistance to RMP or INH was not significantly associated with
time to TB recurrence. Resistance to SMwas significantly associated
with time to TB recurrence in the univariate model [HR ¼ 2.50 (95%
CI, 1.21e5.15)], but not in the multivariate model (Table 3). When
we replaced RMP and INH resistance by MDR in the same model,
MDR was also not significantly associated with recurrence
[aHR ¼ 3.25 (95% CI, 0.71e14.94)] (table not shown). Other char-
acteristics, including HIV coinfection, severity on CXR, and category
of patients' residential areas, were not associated with time to TB
recurrence (Table 3).
4. Discussion
Our study demonstrated that RMP resistance was associated
with treatment failure among patients newly diagnosed with
smear-positive and culture-positive pulmonary TB. In addition,
we found that infection with a modern Beijing strain was a risk
factor for TB recurrence within 16 months of follow-up after
completing treatment for a previous TB episode. In our study
population, the prevalence of INH and SM resistance was higher
among patients infected with ancient Beijing strains than among
those infected with modern Beijing strains; however, INH resis-
tance and SM resistance or infection with ancient Beijing strains
were not associated with the increased risk of treatment failure or
TB recurrence.
Four percent of TB patients had a treatment failure in our
study, similar to 4.3% of TB patients who failed treatment in a
different study conducted in southern Vietnam [32], and 5% in a
multicenter trial conducted in eight centers in Africa and Asia
[33]. These treatment failure rates are higher than those (2%) re-
ported globally [1], in part because of the relatively less effective
treatment regimen, 2S(E)HRZ/6HE, that was used during the
study period at these study sites. The proportion of TB recurrence
was 7.4% in the present study, versus 8.6% in another study con-
ducted in northern Vietnam [34], 6.5% in southern Vietnam [32],
and 5% in the multicenter trial [33] cited above. The longer follow-
up period (32 months as maximum) and less strict criteria used
for diagnosis of TB recurrence in the northern Vietnamese study
[34] may explain the higher proportion of recurrence in that study
compared with our study. Conversely, active monitoring using
periodical sputum testing during the follow-up period may have
improved our detection of TB recurrence, compared with the
passive case finding of TB recurrence used in the study in southern
Vietnam [32].
Table 2
Results of univariate and multivariate analyses using logistic regression models on
sublineages of Beijing genotype and other factors evaluated for an association with
treatment failure (n ¼ 430).
Proportion with
treatment
failure (%)
Univariate Multivariate*
OR 95% CI OR 95% CI
Age (increased
by one year)
1.00 0.96e1.03
Gender
Male 15/341 (4.4) 1.00 (Reference)
Female 2/89 (2.3) 0.50 0.11e2.23
MTB strain
Other strains 3/173 (1.73) 1.00 (Reference) 1.00 (Reference)
Ancient Beijing 6/152 (3.95) 2.33 0.57e9.48 1.38 0.31e6.11
Modern Beijing 6/88 (6.82) 4.15 1.01¡17.00 3.71 0.86e15.96
Resistant to SM
No 7/319 (2.2) 1.00 (Reference) 1.00 (Reference)
Yes 10/111 (9.0) 4.41 1.64¡11.90 1.77 0.46e6.76
Resistant to RMP
No 13/415 (3.1) 1.00 (Reference) 1.00 (Reference)
Yes 4/15 (26.7) 11.24 3.16¡40.07 6.64 1.48¡29.73
Resistant to INH
No 7/317 (2.2) 1.00 (Reference) 1.00 (Reference)
Yes 10/113 (8.9) 4.30 1.60¡11.59 2.34 0.62e8.90
Multidrug resistance
No 13/417 (3.1) 1.00 (Reference)
Yes 4/13 (930.8) 13.81 3.76¡50.72
Presence of infiltrate on CXR
3 zonesy 10/344 (2.9) 1.00 (Reference)
>3 zones 6/70 (8.6) 3.13 1.10¡8.92
Presence of cavity on CXR
No 1/123 (0.8) 1.00 (Reference)
Yes 15/290 (5.2) 6.65 0.87e50.94
Smear at month 2z
Negative 9/373 (2.4) 1.00 (Reference)
Positive 8/56 (14.3) 6.74 2.48¡18.30
HIV infection
No 16/406 (3.9) 1.00 (Reference)
Yes 1/22 (4.6) 1.16 0.15e9.17
Clustered MTB strains
No 10/271 (3.7) 1.00 (Reference)
Yes 5/142 (3.5) 0.95 0.32e2.84
MTB: Mycobacterium tuberculosis; OR: odds ratio; 95% CI: 95% confidence interval;
SM: streptomycin; RMP: rifampicin; INH: isoniazid; HIV: human immunodeficiency
virus; CXR: chest X-ray.
Boldfaced values indicate odds ratios and 95% CI with statistical significance
(P < 0.05).
* In the multivariate analysis, resistance to SM, RMP, and INH, MTB strains
(ancient Beijing, modern Beijing and others) were included in the logistic models.
y Zones of the lung field.
z Two months after starting treatment.
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In the present study, RMP resistance was strongly associated
with treatment failure but not with recurrence. The majority of
RMP-resistant strains had MDR (22/24 or 91.7%), which is a
well-known risk factor for treatment failure [35]. In some
resource-limited settings, drug susceptibility testing is not
performed routinely for new patients before starting treatment.
In those settings, application of necessary countermeasures
against MDR, including a timely change of the treatment
regimen, should be considered once treatment failure is
suspected.
Also in the present study, active disease caused by the Beijing
genotype was associated with an increased risk of TB recurrence,
which was consistent with previous reports from different areas of
the world [10e13]. Interestingly, modern Beijing strains exhibited a
potential risk for recurrence when non-Beijing MTB genotypes
were set as the reference group. Other investigators [36] have
previously reported the high prevalence of modern Beijing strains
among patients with a history of anti-TB treatment, suggesting that
this sublineage may be associated with TB recurrence. Our study
results suggest that the modern Beijing strains influenced TB
recurrence, whereas the ancient Beijing strains did not. There was
no significant difference in the probability of recurrent TB in pa-
tients with ancient versus modern Beijing sublineages. This result
could be due to the low number of recurrent TB patients with the
ancient sublineage in our study, as well as insufficient statistical
power.
Virulent phenotypes of the modern Beijing sublineage strains
could be differentiated by frequent drug resistance mutations and
propagation, or disease development with a short latency period
based on the hostepathogen interaction. In our study, the modern
Beijing sublineage was actually an independent risk factor regard-
less of drug resistance status in the multivariate analysis. Disease
caused by modern Beijing MTB strains conferred a risk of TB
recurrence, despite having less frequent drug resistance than that
caused by the ancient Beijing genotype. Previous reports indicate
that modern Beijing strains produce lower levels of proin-
flammatory cytokines [37,38] and have a higher survival in mac-
rophages [38] than ancient Beijing strains. These factors may
facilitate persistent infection or reactivation from latent infection,
although investigation of these properties at sublineage levels has
only just begun. Nevertheless, these findings could help explain
Figure 2. (A) KaplaneMeier curves illustrating Beijing and non-Beijing MTB lineages and time to recurrence as indicated by the probability of survival with no recurrent tuber-
culosis, (B) KaplaneMeier curves illustrating modern Beijing, ancient Beijing sublineages, non-Beijing lineage, and time to recurrence as indicated by the probability of survival with
no recurrent tuberculosis. Time to recurrence between the Beijing and non-Beijing groups (P ¼ 0.0211 by log rank test). Time to recurrence between the modern Beijing and non-
Beijing groups (P ¼ 0.0213 by log rank test) but not significant in other combinations, including modern Beijing and ancient Beijing sublineages (data not shown). TB: tuberculosis.
Table 3
Results of univariate and multivariate analyses using proportional hazardmodels on
sublineages of Beijing genotype and other factors evaluated for an association with
TB recurrence (n ¼ 403).
Proportion with
recurrence (%)
Univariate Multivariate*
HR 95% CI HR 95% CI
Age (increased
by one year)
1.00 0.98e1.03
Gender
Male 23/316 (7.3) 1.00 (Reference)
Female 7/87 (8.1) 1.15 0.50e2.69
MTB strain
Other strains 6/165 (3.64) 1.00 (Reference) 1.00 (Reference)
Ancient Beijing 13/143 (9.09) 2.55 0.97e6.70 2.08 0.77e5.62
Modern Beijing 9/80 (11.25) 3.16 1.13¡8.89 3.29 1.17¡9.27
Resistant to SM
No 17/306 (5.6) 1.00 (Reference) 1.00 (Reference)
Yes 13/97 (13.4) 2.50 1.21¡5.15 2.33 0.97e5.61
Resistant to RMP
No 28/394 (7.1) 1.00 (Reference) 1.00 (Reference)
Yes 2/9 (22.2) 3.63 0.86e15.26 3.1 0.66e14.55
Resistant to INH
No 20/304 (6.6) 1.00 (Reference) 1.00 (Reference)
Yes 10/99 (10.1) 1.58 0.74e3.38 0.85 0.33e2.19
Smear at month 2y
Negative 24/355 (6.8) 1.00 (Reference)
Positive 6/48 (12.5) 1.84 0.75e4.50
Clustered
No 15/255 (5.9) 1.00 (Reference)
Yes 13/133 (9.8) 1.64 0.78e3.45
Presence of infiltrate on CXR
3 zonesz 26/327 (8.0) 1.00 (Reference)
>3 zones 4/62 (6.5) 0.79 0.27e2.25
Presence of cavity on CXR
No 11/119 (9.2) 1.00 (Reference)
Yes 19/269 (7.1) 0.75 0.36e1.59
HIV infection
No 29/380 (7.6) 1.00 (Reference)
Yes 1/21 (4.8) 0.66 0.09e4.85
TB: tuberculosis; MTB: Mycobacterium tuberculosis; HR: hazard ratio; 95% CI: 95%
confidence interval; SM: streptomycin; RMP: rifampicin; INH: isoniazid; HIV: hu-
man immunodeficiency virus; CXR: chest X-ray.
Boldfaced values indicate hazard ratios and 95% CI with statistical significance
(P < 0.05).
* In the multivariate analysis, resistance to SM, RMP, and INH, MTB strains
(ancient Beijing, modern Beijing and others) were included in the Cox models.
y Two months after starting treatment.
z Zones of the lung field.
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their potential to dysregulate host defense mechanisms, leading to
increased virulence and successful spread of the modern sub-
lineage [14,15,17].
SM resistance unexpectedly exhibited a significant association
with recurrence in the univariate analysis but not in the multivar-
iate analysis. In another study conducted in southern Vietnam [13],
resistance to INH was a risk factor for recurrence. Although direct
evidence is lacking, this inconsistency may be due to area-
dependent differences in the distribution patterns of major Bei-
jing sublineages and their subgroups. Resistance to SM cannot be
overlooked because this antibiotic is still used as a component of
treatment regimens, such as 2SHRZE/1HRZE/5HRE, recommended
byWHO for severe TB or retreated TB cases [39], inwhich relapse is
often observed.
Other factors (e.g., poor treatment adherence, increased dis-
ease severity by expansion of lesions in the lung, HIV coinfection
[4], diabetic status [40], and clustering status possibly indicating
recent transmission) were not associated with TB recurrence by
univariate analysis in our study (P > 0.2, data not shown). For this
reason, they were not included in the multivariate analysis.
Positive smear results at month 2 were significantly associated
with treatment failure. This was consistent with the classical idea
that persistently positive smear testing after the intensive
treatment phase is a possible surrogate for treatment outcome
[41].
The present study has some limitations. First, we were not able
to differentiate relapse from reinfection among recurrent cases.
However, we presume they were true relapse cases because most
of the second TB episodes appeared in a relatively short time after
cure; the median of time to recurrence was 137 days (95% CI,
110e218 days) after the end of treatment. Second, we were unable
to study the host immune response to clarify the mechanism(s)
underlying the association between modern Beijing sublineage
and recurrence. Nevertheless, this is the first report from Vietnam
on the association between MTB sublineages and unfavorable
treatment outcomes, including recurrence. Future subclassifi-
cation of Beijing sublineages through the analysis of genome-wide
variations may help clarify the genotypeephenotype relationship
and may provide an explanation for the inconsistent results pre-
viously reported. In addition, the strength of our cohort study was
supported by a high proportion of patients completing treatment,
followed up actively and intensively, and with clinicoepidemio-
logical data linked to MTB lineages/sublineages with drug-
resistance profiles.
In conclusion, among patients newly diagnosed with smear-
positive pulmonary TB, infection with the modern Beijing sub-
lineage was associated with recurrence, whereas infectionwith the
ancient Beijing sublineage was not. Considering the high preva-
lence of circulating Beijing genotype strains and pretreatment drug
resistance in the study area, multiple factors should be considered
to achieve better TB management.
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